Abstract: The invention relates to fire-extinguishing foams or concentrates, which include a carbohydrate containing silane surfactant.

Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

Abstract: Novel efficient, time-saving and reliable radiofluorination procedures for the production of 18F-labelled active esters via nucleophilic substitution of the corresponding onium precursors with 18F? are described. The active ester including [18F]F-Py-TFP and [18F]TFB produced by one of these methods was used to prepare PSMA-specific PET tracers such as [18F]DCFPyL. The key advantages of these inventive methods are efficiency, short time of preparation and excellent amenability to automation. A pharmaceutical composition containing at least one PSMA-specific PET tracers prepared by the inventive method is useful for positron emission tomography (PET) imaging, especially imaging prostate tumor.

Abstract: A receiving container for a detector which operates in an ultrahigh vacuum or in a protective gas atmosphere that consists of high-purity gas. The receiving container has a receiving portion which forms at least a portion of the receiving space for the detector, and a cover for hermetically sealing the receiving space. A first sealing surface is arranged at the receiving portion and a second sealing surface matching the first sealing surface is arranged at the cover. Between the sealing surfaces a gasket is arranged. A securing device presses the cover against the receiving portion to provide a defined contact pressure of the gasket.

Abstract: A method of culturing Haematococcus species for manufacturing of astaxanthin comprising the steps of: providing a substrate, arranging the Haematococcus species on the surface of the substrate, exposing the Haematococcus species arranged on the substrate to high light intensities from the beginning of a culturing process and avoiding a two-step culturing process of the Haematococcus species with a first step which is an initial culturing taking place by exposure of the Haematococcus species to low light energy followed by a second step of subsequent culturing of the Haematococcus species by exposure of the Haematococcus species to higher light energy than applied in the first step to induce astaxanthin formation, and optionally harvesting the cultured Haematococcus species and/or isolating astaxanthin.

Abstract: Subject matter of the present invention is PSMA Binding molecules for use in diagnosis and/or imaging of pain. Diagnosis or imaging of pain may be the visualization of the location of the origin of pain and/or the determination of the etiology of pain and/or the determination of the pain intensity and/or the stratification of subjects suffering from pain.

Abstract: The present invention relates to an inhibitor of neurocalcin delta (NCALD) for use in a method for the treatment or prevention of a patient suffering from a disorder associated with a pathological calcium homeostasis. Furthermore, the present invention refers to the use of such inhibitor of NCALD for inducing axon proliferation in vitro and to a method for the differentiation and/or maturation of neuronal stem cells (NSCs) in vitro and to the use of such inhibitor of NCALD to restore impaired endocytosis being a consequence of disturbed Ca2+ homeostasis in synaptic terminals essential for development, maturation and maintenance of synapses and neuromuscular junctions (NMJs).

Abstract: The present invention relates to a branched or unbranched free or glycosidically bound polysialic acid according to general formula (1) as given as follows poly-(?(2?8 or 2?9)Neu5Ac)n (1) wherein Neu5Ac is N-acetylneuraminic acid, and n is an integer in the range from 14 to 26 and/or pharmaceutically acceptable salts thereof, a polysaccharide composition comprising the polysialic acid (1), and the use as a medicament, particularly in the therapeutic and/or prophylactic treatment of degenerative, demyelinating and inflammatory diseases of the central nervous system, and degenerative or inflammatory retinal diseases.

Abstract: A receiving container for a detector which operates in an ultrahigh vacuum or in a protective gas atmosphere that consists of high-purity gas. The receiving container has a receiving portion which forms at least a portion of the receiving space for the detector, and a cover for hermetically sealing the receiving space. A first sealing surface is arranged at the receiving portion and a second sealing surface matching the first sealing surface is arranged at the cover. Between the sealing surfaces a gasket is arranged. A securing device presses the cover against the receiving portion to provide a defined contact pressure of the gasket.

Abstract: The invention relates to fire extinguishing foams or concentrates thereof, these comprising a carbohydrate-containing siloxane surfactant.

Abstract: A method for coating a separator for a fuel cell is provided that includes vaporizing a metal carbide precursor to obtain a precursor gas; introducing a metal carbide coating layer-forming gas including the precursor gas in a reaction chamber; and applying a voltage to the reaction chamber so that the precursor gas is changed into a plasma state, thereby forming a metal carbide coating layer on either surface or both surfaces of a substrate. In this case, the metal carbide precursor may include a compound having a substituted or non-substituted cyclopentadienyl group.

Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

Abstract: The invention relates to fire extinguishing foams or concentrates thereof, these comprising a carbohydrate-containing siloxane surfactant.

Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

Abstract: The invention relates to fire-extinguishing foams or concentrates, which include a carbohydrate containing silane surfactant.

Abstract: The invention discloses in vitro methods and a system for determining a predisposition of a subject for developing a cancer on the basis of analyzing a sample of the subject for an alteration of at least one allele of the RAD51C gene. Further disclosed are in vitro methods for assessing clinical features or a pathological progression of a cancer and for assessing at least one RAD51 C gene alteration in a cell. In addition a kit for determining a predisposition of a subject for developing a cancer, and certain uses of oligonucleotides for determining the presence of at least one mono-allelic germ-line mutation of the RAD51C gene.

Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

Abstract: The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with solid tumors, like colorectal cancer, and for monitoring the progression of solid tumors, like colorectal cancer, in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with solid tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.

Abstract: The invention relates to fire extinguishing foams or concentrates thereof, these comprising a carbohydrate-containing siloxane surfactant.

Abstract: Substituted tricyclic diproline analogues of the formula (I): wherein the variables are as defined herein. Also disclosed are methods for the production thereof, the use thereof for the induction of an alpha-helix conformation in peptides and/or proteins, pharmaceuticals containing said compounds, methods for the production of a peptide library containing said compounds, and peptide libraries containing said compounds.